After Hours Top Loser: NWRN.SW Newron Pharmaceuticals (SIX) 25 Mar 2026: Oversold

NWRN.SW stock fell to CHF 14.64 in after-hours trade on 25 Mar 2026, marking a short-term downshift as investors digest recent weakness. The move follows a 1M decline of 24.87% and YTD fall of 44.31%, making Newron Pharmaceuticals a top loser on the SIX after session. Volume ran above average at 196,421 versus an average of 145,268, signalling heavier selling pressure that pushed technical indicators into oversold territory.

NWRN.SW stock price action and market context

Newron Pharmaceuticals (NWRN.SW) closed the regular session at CHF 14.64, down -2.40% on the day with a day low of CHF 14.06 and a day high of CHF 14.92. Trades were active: volume reached 196,421 against an average volume of 145,268, giving a relative volume of 1.64. The stock sits well below its 50-day average of CHF 19.96 but near the 200-day average of CHF 14.42, reflecting mixed medium-term momentum on the SIX in Switzerland.

Fundamentals and valuation snapshot for NWRN.SW stock

Fundamentals show an EPS of 1.25 and a reported PE ratio near 11.36, which looks inexpensive versus healthcare peers. Market capitalization is approximately CHF 283,446,115 with 19,960,994 shares outstanding. Key balance metrics: current ratio 1.51, cash per share CHF 2.16, and free cash flow per share CHF 1.23. Price-to-sales is 5.17 and price-to-book sits unusually high at ~195.72, driven by low reported book value per share (0.08). These mixed metrics point to strong profitability but thin reported equity, common in biotech firms with intangible R&D assets.

Technical outlook and why the stock is a top loser

Technically, NWRN.SW stock shows classic oversold signals: RSI 22.04, Williams %R -80.39, and a negative MACD histogram. The 1-month decline is -24.87% and 3-month decline is -41.92%, which explains its placement among top losers after hours. Bollinger Bands place a lower band near CHF 13.99, which could act as short-term support. Traders should note an ATR of 1.21, emphasising elevated intraday volatility.

Meyka AI grade, forecast and model view

Meyka AI rates NWRN.SW with a score out of 100: 76.14 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly target of CHF 23.38, implying an upside of 59.70% from the current price of CHF 14.64. Forecasts are model-based projections and not guarantees. The model also lists monthly and multi-year targets (monthly CHF 15.40, 3-year CHF 37.07).

Catalysts, sector context and risk factors

Newron operates in Biotechnology within Healthcare; the sector is down YTD -7.38%, weighing on sentiment. Positive catalysts include regulatory updates for Xadago or clinical readouts for Evenamide and ralfinamide, while risks include trial setbacks, pricing pressure and the company’s reported debt structure metrics where debt-to-equity reads high in some reports. Institutional flow and sector rotations can amplify moves; the near-term chart looks driven by sentiment rather than fresh fundamentals.

Trading implications and short-term strategy

For short-term traders, elevated volume (196,421) and oversold indicators suggest a bounce play near CHF 13.99–14.06 support with a tight stop below that band. For longer-term investors, valuation metrics such as PE 11.36 and FCF yield near 7.92% may justify accumulation on confirmation of clinical or revenue catalysts. Position sizing should reflect biotech volatility and the stock’s 1M drop of 24.87%.

Final Thoughts

NWRN.SW stock is trading at CHF 14.64 after hours on 25 Mar 2026, and its placement among top losers is driven by a steep 1M decline of 24.87%, oversold technicals (RSI 22.04) and above-average volume (196,421). Fundamentals remain mixed: EPS 1.25 and PE 11.36 contrast with a high price-to-book near 195.72, reflecting low reported equity. Meyka AI’s forecast model projects a yearly target of CHF 23.38, implying ~59.70% upside from today’s price, but forecasts are model-based projections and not guarantees. Investors should weigh clinical readouts and regulatory catalysts against sector weakness and short-term volatility. We include Meyka AI as an AI-powered market analysis platform for data context, and investors should use the grade and forecast as one input among many when sizing positions and setting risk limits.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.